Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02397499 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat
A Phase 3 study, sponsored by Neothetics.
- Completed
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
NCT02397499 is a Phase 3 study that has completed, run by Neothetics. The registered enrollment target is 800 participants.
The verdict
NCT02397499, a Phase 3 study, has completed, sponsored by Neothetics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
Interventions
- DRUG Placebo
- DRUG LIPO-202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2015-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02397499
The ClinicalTrials.gov registry entry for NCT02397499 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neothetics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02397499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02397499 about?
NCT02397499 is a clinical study titled "Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat". This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
What is the current status of trial NCT02397499?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2015-04.
What interventions are being tested in trial NCT02397499?
The interventions under investigation include: Placebo (DRUG), LIPO-202 (DRUG).
Who is sponsoring clinical trial NCT02397499?
This trial is sponsored by Neothetics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.